Company Encyclopedia
View More
name
Motley Fool Small-Cap Growth ETF
TMFS.US
News
View More

HealthEquity, Inc. $HQY Shares Bought by DAVENPORT & Co LLC

DAVENPORT & Co LLC increased its stake in HealthEquity, Inc. by 23.9% in Q3, owning 386,388 shares valued at $36.77 million. Other institutional investors also adjusted their holdings. HealthEquity's stock opened at $92.69, with a market cap of $7.92 billion. The company reported Q3 earnings of $1.01 per share, surpassing estimates, and revenue of $322.16 million, up 7.2% year-over-year. Analysts set a price target of $125.00 for the stock.

Market Beat·
US
HQY
+0.11%
Market Beat·
US
HQY
+0.11%

Alternative commercialisation models offer lifeline to future of gene therapies

The article discusses the future of gene therapies, emphasizing alternative commercialization models by non-profits. It highlights Waskyra's FDA approval, a gene therapy for Wiskott-Aldrich Syndrome, developed by Fondazione Telethon, marking a milestone as the first non-profit developed gene therapy approved. Challenges like manufacturing complexities and regulatory hurdles are noted, with a call for flexible regulatory pathways for rare diseases.

Pharmaceutical Technology·
US
RARE
+1.20%
Pharmaceutical Technology·
US
RARE
+1.20%

HealthEquity Inc. EVP and General Counsel Delano Ladd Reports Sale of Common Shares

Delano Ladd, EVP and General Counsel of HealthEquity Inc., reported the sale of common shares of the company. The information was published via EDGAR by HealthEquity Inc. on December 23, 2025. This brief was created by Public Technologies using AI and is for informational purposes only.

Reuters·
US
HQY
+0.11%
Reuters·
US
HQY
+0.11%

If I'd Listened To My Doctor, I Would Be Dead Right Now

The author recounts a personal experience where a doctor's dismissal of symptoms nearly cost her life. Initially, her OB-GYN downplayed the urgency of a concerning tumor, delaying necessary procedures. Trusting her instincts, she sought a second opinion, leading to a diagnosis of rare cancer. This highlights the importance of advocating for one's health and seeking multiple medical opinions when necessary.

Yahoo Finance·
US
RARE
+1.20%
Yahoo Finance·
US
RARE
+1.20%

Did Herc’s US$1.2 Billion Note Refinancing Just Shift Herc Holdings' (HRI) Investment Narrative?

Herc Holdings Inc. refinanced US$1.2 billion in senior notes, extending maturities to 2031 and 2034 with higher interest rates. This move reshapes its debt profile, impacting credit risk and financial flexibility. Despite the refinancing, Herc's high leverage and weaker free cash flow remain key risks. The company's investment narrative projects significant revenue and earnings growth by 2028, with fair value estimates ranging from US$168 to US$223 per share. Recent board changes aim to strengthen oversight of capital structure and risk controls.

Simplywall·
US
HRI
+0.31%
Simplywall·
US
HRI
+0.31%
© 2025 Longbridge｜Disclaimer